641571-13-3

Basic information

• Product Name: 3-(4-Methylimidazol-1-yl)-5-trifluoromethylbenzoic acid
• Synonyms: 3-(4-Methylimidazol-1-yl)-5-trifluoromethylbenzoic acid;3-(4-METHYL-1H-IMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)BENZOIC ACID;Nilotinib Impurity 14
• CAS NO: 641571-13-3
• Molecular Formula: C₁₂H₉F₃N₂O₂
• Molecular Weight: 270.21
• Product Categories: API intermediates
• Mol File: 641571-13-3.mol

Chemical Properties

• Boiling Point: 423.524 °C at 760 mmHg
• Flash Point: 209.94 °C
• Appearance: /
• Density: 1.407 g/cm³
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-(4-Methylimidazol-1-yl)-5-trifluoromethylbenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-Methylimidazol-1-yl)-5-trifluoromethylbenzoic acid(641571-13-3)
• EPA Substance Registry System: 3-(4-Methylimidazol-1-yl)-5-trifluoromethylbenzoic acid(641571-13-3)

Safety Data

• Hazardous Substances Data: 641571-13-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-(4-Methylimidazol-1-yl)-5-trifluoromethylbenzoic acid is used as a synthetic reagent for the preparation of pyrrolo[2,3-d]pyrimidine derivatives, which exhibit antitumor activity against A375 human melanoma cells. Its unique chemical structure allows it to be a valuable component in the development of novel therapeutic agents targeting cancer cells.
Used in Anticancer Applications:
In the field of oncology, 3-(4-Methylimidazol-1-yl)-5-trifluoromethylbenzoic acid is utilized for its potential role in the synthesis of compounds with antitumor properties. The pyrrolo[2,3-d]pyrimidine derivatives prepared using this reagent have demonstrated effectiveness against melanoma, a type of skin cancer, highlighting its importance in the development of targeted cancer treatments.

Upstream product

• 822-36-6 4-methyl-1H-imidazole 
• 161622-05-5 3-fluoro-5-(trifluoromethyl)benzoic acid 
• 328-67-6 3-bromo-5-(trifluoromethyl)benzoic acid 
• 149793-69-1 3-fluoro-5-trifluoromethyl-benzonitrile 
• 641571-12-2 3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzonitrile 

Downstream Products

• 677704-46-0 3-(4-methyl-1H-imidazol-1-yl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-5-(trifluoromethyl)benzamide 
• 1237750-52-5 3-(4-methyl-1H-imidazol-1-yl)-N-(4-methyl-3-(1-methyl-7-(methylthio)-2-oxo-1,2-dihydropyrimido[4,5-d]pyrimidin-3(4H)-yl)phenyl)-5-(trifluoromethyl)benzamide 
• 1370335-41-3 C₂₂H₂₁F₃N₄O₃ 
• 641571-11-1 3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)aniline 
• 1261242-36-7 N-(2-((4-(6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl)pyrimidin-2-yl)amino)ethyl)-3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzamide 
• 1370335-61-7 C₁₄H₁₅F₃N₄O 
• 851319-33-0 4-chloro-pyrrolo[2,3-d]pyrimidine-7-carboxylic acid {2-methyl-5-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-benzoylamino]-phenyl}-amide 
• 1240322-54-6 5-{2-methyl-5-[3-(4-methyl-imidazol-1-yl)-5-(trifluoromethyl)benzoylamino]-benzylamino}-1H-pyrrolo[2,3-b]pyridine-2-carboxylic acid methyl ester 

Relevant articles and documents

AN IMPROVED PROCESS FOR 3-(4-METHYL-1H-IMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL) ANILINE

The present invention relates to an improved process for the preparation of 3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl) aniline of Formula (I).

3 - (4 - Methyl - 1 H - imidazole - 1 - yl) - 5 - (trifluoromethyl) aniline preparation method

The invention provides a preparation method for 3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)aniline. The method includes: S1. subjecting a compound A and 4-methyl-1H-imidazole to coupling reaction to generate a coupling product; S2. carrying out hydrazinolysis reaction on the coupling product to generate a hydrazinolysis product; and S3. subjecting the hydrazinolysis product to diazotization and Curtius rearrangement reaction in order to generate 3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)aniline. Specifically, the compound A is 3-halogen-5-trifluoromethylbenzoic acid, a salt derivative of 3-halogen-5-trifluoromethylbenzoic acid or an ester derivative of 3-halogen-5-trifluoromethylbenzoic acid. The method for preparation of 3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)aniline provided by the invention has the characteristics of short synthesis route, low cost of raw materials, mild reaction conditions and high yield, thus being applicable to large-scale industrial production.

PROTEIN KINASE INHIBITORS

The present invention relates to compounds of the following formula (I) and/or the pharmaceutically acceptable addition salts, solvates, enantiomers, diastereoisomers thereof, as well as mixtures thereof. The subject matter of the present invention thus also includes the preparation of compounds of formula (I), their uses, in particular in the inhibition of protein kinases which are implicated for example in numerous diseases such as cancers or immune system disorders.

AZAINDOLE DERIVATIVES AS MULTI KINASE INHIBITORS

The present invention relates to compounds of the following formula (I) and/or the pharmaceutically acceptable addition salts, solvates, enantiomers, diastereoisomers thereof, as well as mixtures thereof. The subject matter of the present invention thus also includes the preparation of compounds of formula (I), their uses, in particular in the inhibition of protein kinases which are implicated for example in numerous diseases such as cancers or immune system disorders.

A type-ii kinase inhibitor capable of inhibiting the T315I "Gatekeeper" mutant of Bcr-Abl

The second generation of Bcr-Abl inhibitors nilotinib, dasatinib, and bosutinib developed to override imatinib resistance are not active against the T315I "gatekeeper" mutation. Here we describe a type-II T315I inhibitor 2 (GNF-7), based upon a 3,4-dihydr

COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA

The invention provides a class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent malaria.

AMINOPYRIMIDINE COMPOUNDS AND THEIR SALTS, PROCESS FOR PREPARATION AND PHARMACEUTICAL USE THEREOF

The present invention provides aminopyrimidine compounds of formula (I) and their salts, wherein R1, R2, R3, R4, R5, R6, Q, Z, L, m, n are defined as the description, the methods for preparation thereof, the uses thereof and the pharmaceutical compositions comprising the effective amount of compounds of formula (I). The compounds of formula (I) and their salts can be used as protein kinase inhibitors.

CHEMICAL COMPOUNDS

The invention relates to chemical compounds, or pharmaceutically acceptable salts thereof, of the formula (I): which possess B-Raf inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.

INHIBITORS OF TYROSINE KINASES

The invention relates to compounds of formula (I) Wherein the substituents R1, R2 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, especially a neoplastic disease, in particular leukaemia, and a method for the treatment of such disease.

NOVEL PYRIMIDINEAMIDE DERIVATIVES AND THE USE THEREOF

The invention relates to novel substituted N-(3-benzoylaminophenyl)-4-pyridyl-2-pyrimidinarnine derivatives, processes for the preparation thereof, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more oth